|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Amira Pharmaceuticals Inc., of San Diego, reported positive data from a Phase I trial of AM103, its lead compound, showing that a single dose of the drug achieves highly significant inhibition of leukotriene synthesis. AM103 is an oral, next-generation inhibitor of the 5-lipoxygenase-activating protein (FLAP) and has demonstrated potential in asthma and cardiovascular disease by preventing the synthesis of leukotrienes, biological compounds that lead to inflammation. Final data from the study are expected in the fourth quarter.
o Genzyme Corp., of Cambridge, Mass., reported positive results from its Study of the Treatment of Articular Repair (STAR) on the safety ...